Literature DB >> 26035190

Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys.

Chadi A Calarge1, Trudy L Burns, Janet A Schlechte, Babette S Zemel.   

Abstract

OBJECTIVE: In a previous cross-sectional study, we found lower bone mass during treatment with selective serotonin reuptake inhibitors (SSRIs) and risperidone in youths. Here, we evaluate the skeletal effects of these psychotropics at follow-up.
METHOD: Between April 2005 and July 2011, medically healthy 7- to 17-year-old males treated with risperidone for 6 months or more were enrolled through child psychiatry outpatient clinics and returned for follow-up 1.5 years later. Treatment history was extracted from the medical and pharmacy records. Anthropometric, laboratory, and bone mass measurements were obtained. Multivariable linear regression analyses compared participants who remained on risperidone at follow-up to those who had discontinued risperidone treatment as well as SSRI-treated versus SSRI-unexposed participants.
RESULTS: The sample consisted of 94 boys with a mean age of 11.8 ± 2.7 years at study entry. The majority had an externalizing disorder and had received risperidone and SSRIs for 2.5 ± 1.7 years and 1.6 ± 1.9 years, respectively, at study entry. By follow-up, 26% (n = 24) had discontinued risperidone. Compared to discontinuing risperidone, continuing it was associated with a decline in participants' age-sex-height-race-specific areal bone mineral density (BMD) z score at the lumbar spine (P < .04) and failure to increase radius trabecular volumetric BMD (P < .03), after accounting for significant covariates. In addition, receiving an SSRI was associated with reduced lumbar spine areal BMD z score and radius trabecular volumetric BMD at both study entry (P < .02 and P < .03, respectively) and follow-up (P < .06 and P < .03, respectively), but without further decline between the 2 visits.
CONCLUSIONS: Chronic SSRI treatment in children and adolescents is associated with reduced, albeit stable, bone mass for age, while chronic risperidone treatment is associated with failure to accrue bone mass. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26035190      PMCID: PMC6734561          DOI: 10.4088/JCP.14m09195

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

1.  Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys.

Authors:  Chadi A Calarge; James A Mills; Lefkothea Karaviti; Antonio L Teixeira; Babette S Zemel; Jose M Garcia
Journal:  J Pediatr       Date:  2018-06-27       Impact factor: 4.406

2.  Nutrition and Bone Density in Boys with Autism Spectrum Disorder.

Authors:  Ann M Neumeyer; Natalia Cano Sokoloff; Erin I McDonnell; Eric A Macklin; Christopher J McDougle; Tara M Holmes; Jane L Hubbard; Madhusmita Misra
Journal:  J Acad Nutr Diet       Date:  2018-03-02       Impact factor: 4.910

Review 3.  The Impact of Psychotropic Medications on Bone Health in Youth.

Authors:  Jessie N Rice; Carrie B Gillett; Nasuh M Malas
Journal:  Curr Psychiatry Rep       Date:  2018-09-24       Impact factor: 5.285

4.  CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders.

Authors:  Madelyn A Gillentine; Ricardo Lozoya; Jiani Yin; Christopher M Grochowski; Janson J White; Christian P Schaaf; Chadi A Calarge
Journal:  J Affect Disord       Date:  2018-07-11       Impact factor: 4.839

5.  Bone Density in Adolescents and Young Adults with Autism Spectrum Disorders.

Authors:  Laya Ekhlaspour; Charumathi Baskaran; Karen Joanie Campoverde; Natalia Cano Sokoloff; Ann M Neumeyer; Madhusmita Misra
Journal:  J Autism Dev Disord       Date:  2016-11

6.  Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis.

Authors:  C Zhou; L Fang; Y Chen; J Zhong; H Wang; P Xie
Journal:  Osteoporos Int       Date:  2018-02-12       Impact factor: 4.507

7.  Bone Accrual in Males with Autism Spectrum Disorder.

Authors:  Ann M Neumeyer; Natalia Cano Sokoloff; Erin McDonnell; Eric A Macklin; Christopher J McDougle; Madhusmita Misra
Journal:  J Pediatr       Date:  2016-11-22       Impact factor: 4.406

8.  CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents.

Authors:  Madelyn A Gillentine; Janson J White; Christopher M Grochowski; James R Lupski; Christian P Schaaf; Chadi A Calarge
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-08-17       Impact factor: 2.576

9.  Bone Mineral Density in Boys Diagnosed with Autism Spectrum Disorder: A Case-Control Study.

Authors:  Kelly Barnhill; Lucas Ramirez; Alan Gutierrez; Wendy Richardson; C Nathan Marti; Amy Potts; Rebeca Shearer; Claire Schutte; Laura Hewitson
Journal:  J Autism Dev Disord       Date:  2017-11

10.  Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study.

Authors:  Chadi A Calarge; James A Mills; Ekhard E Ziegler; Janet A Schlechte
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-11-07       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.